Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2010-022946-25Phase 3
Phase 3, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Primary endpoints: Feasibility, Toxicity and 2 more.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2010-022946-25.